Research progress on nanobody-drug conjugate
10.16438/j.0513-4870.2023-1324
- VernacularTitle:纳米抗体偶联药物的研究进展
- Author:
Xue-yan ZHANG
;
Bai-song ZHOU
;
Yu-lin LIU
- Publication Type:Research Article
- Keywords:
nanobody;
antibody-drug conjugate;
nanobody-drug conjugate
- From:
Acta Pharmaceutica Sinica
2024;59(5):1210-1217
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugate (ADC) has become an effective method for treating various diseases, especially cancer, due to its clear target and good selectivity in clinical practice. However, the monoclonal antibodies in traditional ADC have poor tissue permeability, high modification costs, pose risks such as immunogenicity and immunotoxicity. The nanobody (Nb) which is extracted from the blood of camel animals, is the smallest antibody fragment known to have complete antigen binding ability. It has advantages such as strong tissue permeability, strong specificity, low immunogenicity, and high stability, and can replace traditional monoclonal antibodies to participate in the construction of nanobody-drug conjugate (NDC). This article reviews and discusses the advantages of Nb structure, the construction and application of NDC in the hope of providing ideas for the research and development of NDC.
